دوره 12، شماره 5 - ( 7-1400 )
جلد 12 شماره 5 صفحات 710-703 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Karimi N, Boostani R, Fatehi F, Panahi A, Okhovat A A, Ziaadini B, et al . Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients. BCN 2021; 12 (5) :703-710
URL: http://bcn.iums.ac.ir/article-1-2223-fa.html
URL: http://bcn.iums.ac.ir/article-1-2223-fa.html
Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients. مجله علوم اعصاب پایه و بالینی. 1400; 12 (5) :703-710
چکیده:
Introduction: Guillain-Barre Syndrome (GBS) is an autoimmune acute inflammatory demyelinating polyneuropathy usually elicited by an upper respiratory tract infection. Several studies reported GBS associated with Coronavirus Disease 2019 (COVID-19) infection. In this study, we described nine GBS patients following the COVID-19 vaccine.
Methods: In this study, nine patients were introduced from six referral centers for neuromuscular disorders in Iran between April 8 and June 20, 2021. Four patients received the Sputnik V, three patients received the Sinopharm, and two cases received the AstraZeneca vaccine. All patients were diagnosed with GBS evidenced by nerve conduction studies and/or cerebrospinal fluid analysis.
Results: The median age of the patients was 54.22 years (ranged 26-87 years), and seven patients were male. The patients were treated with Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PLEX). All patients were discharged with some improvements.
Conclusion: The link between the COVID-19 vaccine and GBS is not well understood. Given the prevalence of GBS over the population, this association may be coincidental; therefore, more studies are needed to investigate a causal relationship.
Methods: In this study, nine patients were introduced from six referral centers for neuromuscular disorders in Iran between April 8 and June 20, 2021. Four patients received the Sputnik V, three patients received the Sinopharm, and two cases received the AstraZeneca vaccine. All patients were diagnosed with GBS evidenced by nerve conduction studies and/or cerebrospinal fluid analysis.
Results: The median age of the patients was 54.22 years (ranged 26-87 years), and seven patients were male. The patients were treated with Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PLEX). All patients were discharged with some improvements.
Conclusion: The link between the COVID-19 vaccine and GBS is not well understood. Given the prevalence of GBS over the population, this association may be coincidental; therefore, more studies are needed to investigate a causal relationship.
نوع مطالعه: Original |
موضوع مقاله:
Clinical Neuroscience
دریافت: 1400/4/20 | پذیرش: 1400/6/13 | انتشار: 1400/6/10
دریافت: 1400/4/20 | پذیرش: 1400/6/13 | انتشار: 1400/6/10
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
